Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

Completed

Phase 1 Results N/A

Main Contacts

Name Phone E-mail
Email contact via H. Lundbeck A/S Study Director

Other Locations

Name City State Country Status
FR002 Paris France Unknown_status_icon
NL005 Breda Netherlands Unknown_status_icon
GB001 Glasgow United Kingdom Unknown_status_icon
FI004 Helsinki Finland Unknown_status_icon
SG003 Singapore Singapore Unknown_status_icon